{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:19:34Z","timestamp":1793740774252,"version":"4.6.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Biologic evidence suggests that angiotensin II may play a role in tumor progression or growth. We compared the short-term colorectal cancer (CRC) risk among initiators of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) versus guideline-recommended clinical alternatives (beta blockers, calcium channel blockers [CCB], and thiazides).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a new-user cohort study on U.S. Medicare beneficiaries aged over 65 years, who initiated antihypertensive monotherapy during 2007\u20132013 and were free of cancer diagnosis before drug initiation. Follow-up began 6 months postinitiation to allow time for the diagnostic delay. We estimated hazard ratios (HR) with 95% confidence intervals (CI) using propensity score weighted Cox regression, overall and stratified by time since drug initiation, and 5-year cumulative risk differences (RD) using Kaplan\u2013Meier estimator. We assessed the potential for unmeasured confounding using supplemental data from Medicare Current Beneficiary Survey.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>For analyses without censoring for treatment changes, we observed 532 CRC events among 111,533 ACEI\/ARB initiators. After a median follow-up of 2.2 years (interquartile range: 1.0\u20133.7), CRC risk was similar between ACEI\/ARB and active comparators, with adjusted HRs of 1.0 (95% CI = 0.85, 1.1) for ACEI\/ARB versus beta blockers, 1.2 (95% CI = 0.97, 1.4) for ACEI\/ARB versus CCB and 1.0 (95% CI = 0.80, 1.3) for ACEI\/ARB versus thiazide. Five-year RDs and as-treated analyses, which censored follow-up at medication changes, produced similar findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Based on real-world antihypertensive utilization patterns in Medicare beneficiaries, our study suggests no association between ACEI\/ARB initiation and the short-term CRC risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ede.0000000000001065","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T07:17:11Z","timestamp":1564125431000},"page":"867-875","source":"Crossref","is-referenced-by-count":17,"title":["Renin\u2013Angiotensin\u2013Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries"],"prefix":"10.1097","volume":"30","author":[{"given":"Phyo T.","family":"Htoo","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Til","family":"St\u00fcrmer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Jonsson-Funk","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pate","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross J.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of North Carolina at Chapel Hill, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230908","first-page":"141","article-title":"Neovascularization produced by angiotensin II.","volume":"105","author":"Fernandez","year":"1985","journal-title":"J Lab Clin Med"},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","article-title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia.","volume":"339","author":"Folkman","year":"1989","journal-title":"Nature"},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/01.RES.68.2.450","article-title":"Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.","volume":"68","author":"Daemen","year":"1991","journal-title":"Circ Res"},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00419.2002","article-title":"ANG II stimulates PKC-dependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells.","volume":"285","author":"Chiu","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R6-20230908","first-page":"6726","article-title":"Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.","volume":"63","author":"Yasumaru","year":"2003","journal-title":"Cancer Res"},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.","volume":"29","year":"2011","journal-title":"J Hypertens"},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"1470320316656679","DOI":"10.1177\/1470320316656679","article-title":"Renin-angiotensin system blockade for the risk of cancer and death.","volume":"17","author":"Shen","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer.","volume":"7","author":"Azoulay","year":"2012","journal-title":"PLoS One"},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis.","volume":"167","author":"Wang","year":"2013","journal-title":"Int J Cardiol"},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"djt374","DOI":"10.1093\/jnci\/djt374","article-title":"Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.","volume":"106","author":"Makar","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study.","volume":"74","author":"Hallas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1158\/1055-9965.EPI-08-0095","article-title":"Cardiovascular medication use and risk for colorectal cancer.","volume":"17","author":"Boudreau","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pds.1656","article-title":"Long-term use of antihypertensive drugs and risk of cancer.","volume":"17","author":"Assimes","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.","volume":"344","author":"Bhaskaran","year":"2012","journal-title":"BMJ"},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: the Rotterdam Study.","volume":"112","author":"van der Knaap","year":"2008","journal-title":"Cancer"},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium channel blockers and the risk of cancer.","volume":"279","author":"Rosenberg","year":"1998","journal-title":"JAMA"},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10552-015-0617-1","article-title":"Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.","volume":"26","author":"Dai","year":"2015","journal-title":"Cancer Causes Control"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians.","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med"},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology.","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s40471-018-0155-y","article-title":"The importance and implications of comparator selection in pharmacoepidemiologic research.","volume":"5","author":"D\u2019Arcy","year":"2018","journal-title":"Curr Epidemiol Rep"},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","article-title":"Calcium-channel blockers and risk of cancer.","volume":"349","author":"Jick","year":"1997","journal-title":"Lancet"},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","article-title":"Calcium-channel blockade and incidence of cancer in aged populations.","volume":"348","author":"Pahor","year":"1996","journal-title":"Lancet"},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"e009147","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD).","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"key":"R27-20230908","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study.","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"R28-20230908","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357909009012067","article-title":"Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study.","volume":"8","author":"Zacharski","year":"1990","journal-title":"Cancer Invest"},{"key":"R29-20230908","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1097\/MD.0000000000001097","article-title":"Propranolol reduces cancer risk: a population-based cohort Study.","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R30-20230908","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1002\/cncr.26727","article-title":"Beta blocker use and colorectal cancer risk: population-based case-control study.","volume":"118","author":"Jansen","year":"2012","journal-title":"Cancer"},{"key":"R31-20230908","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CEJ.0000000000000218","article-title":"Adrenergic blockers and the risk for common solid cancers: a case-control study.","volume":"26","author":"Numbere","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"R32-20230908","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"R35-20230908","doi-asserted-by":"crossref","first-page":"343.e2","DOI":"10.1016\/j.jclinepi.2011.09.002","article-title":"Tradeoffs between accuracy measures for electronic health care data algorithms.","volume":"65","author":"Chubak","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"R36-20230908","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10552-007-0131-1","article-title":"Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data.","volume":"18","author":"Setoguchi","year":"2007","journal-title":"Cancer Causes Control"},{"key":"R37-20230908","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/oxfordjournals.aje.a113189","article-title":"Induction and latent periods.","volume":"114","author":"Rothman","year":"1981","journal-title":"Am J Epidemiol"},{"key":"R38-20230908","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2013viewpoint of the IARC working Group.","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"R39-20230908","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ijc.23033","article-title":"Tobacco smoking and cancer: a meta-analysis.","volume":"122","author":"Gandini","year":"2008","journal-title":"Int J Cancer"},{"key":"R40-20230908","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/aje\/kwi192","article-title":"Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration.","volume":"162","author":"St\u00fcrmer","year":"2005","journal-title":"Am J Epidemiol"},{"key":"R41-20230908","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R42-20230908","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization.","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"key":"R43-20230908","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R44-20230908","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/aje\/kwu122","article-title":"Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy.","volume":"181","author":"Cole","year":"2015","journal-title":"Am J Epidemiol"},{"key":"R45-20230908","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-011-2242-1","article-title":"Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias.","volume":"54","author":"Johnson","year":"2011","journal-title":"Diabetologia"},{"key":"R46-20230908","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1055-9965.EPI-06-0391","article-title":"Metabolic abnormalities and risk for colorectal cancer in the physicians\u2019 health study.","volume":"15","author":"St\u00fcrmer","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R47-20230908","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bjc.2014.579","article-title":"Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis.","volume":"112","author":"Bagnardi","year":"2015","journal-title":"Br J Cancer"},{"key":"R48-20230908","doi-asserted-by":"crossref","first-page":"g4490","DOI":"10.1136\/bmj.g4490","article-title":"Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies.","volume":"349","author":"Wang","year":"2014","journal-title":"BMJ"},{"key":"R49-20230908","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40264-015-0382-9","article-title":"Use of prescription drug samples in the USA: a descriptive Study with considerations for pharmacoepidemiology.","volume":"39","author":"Hampp","year":"2016","journal-title":"Drug Saf"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T11:36:40Z","timestamp":1694173000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001065","relation":{},"ISSN":["1044-3983"],"issn-type":[{"value":"1044-3983","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}